Premas Biotech: Premas Biotech Reports Positive Preliminary Phase-1 Data for its Oral Covid-19 Vaccine, developed for Oravax Medical

Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical Inc Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from the baseline Trial shows proof of concept for oral delivery of vaccines using Oravax technology GURUGRAM, India, Oct. Continue reading Premas Biotech Reports Positive Preliminary Phase-1 Data for its Oral Covid-19 Vaccine, developed for Oravax Medical at Life Care News.